Manipal Health Enterprises IPO subscribed 3.9 times on closing day
Manipal Health Enterprises' Rs 8,000 crore fresh-issue IPO was subscribed 3.9 times by the afternoon of its closing day on 31 July, led by institutional buyers, per NSE data.
The Development
Manipal Health Enterprises Limited's initial public offering closed on 31 July 2026 after a three-day bidding window, and by the afternoon of the final day the issue had been subscribed 3.88 times, per subscription data published by the National Stock Exchange. The book was led by qualified institutional buyers, whose portion was subscribed 6.68 times as of 14:48 on the closing day, while the non-institutional and retail portions remained below full subscription at 0.50 times and 0.67 times respectively.
The offer is among the largest mainboard issues of the year. It comprises a fresh issue of equity shares aggregating up to Rs 8,000 crore and an offer for sale of up to 2,16,13,834 equity shares, at a price band of Rs 560 to Rs 590 per share, per the red herring prospectus filed with SEBI on 24 July 2026. The three-day window ran from 29 to 31 July 2026, and the closing-day strength in the institutional book followed an anchor allocation of 7,06,28,768 equity shares ahead of the opening, per the offer document. The development was surfaced through IPO coverage in The Economic Times.
The Company
Manipal Health Enterprises operates a pan-India network of multispecialty hospitals. As of 31 March 2026 the company operated 49 hospitals, including six operated-and-managed facilities, with 13,037 licensed beds across its network, per the RHP. Its hospitals are concentrated in Karnataka, where the company discloses it derived 46.40% of its revenue from operations in Fiscal 2026. Flagship facilities include Kasturba Hospital in Manipal, Karnataka.
On the financials disclosed in the offer document, Manipal Health reported revenue from operations of Rs 10,335.75 crore in Fiscal 2026, up from Rs 8,242.25 crore in Fiscal 2025 and Rs 6,171.63 crore in Fiscal 2024. Profit for the year was Rs 916.52 crore in Fiscal 2026, against Rs 1,081.67 crore in Fiscal 2025 and Rs 533.20 crore in Fiscal 2024, per the restated consolidated statements in the RHP. EBITDA for Fiscal 2026 stood at Rs 2,721.87 crore, the company discloses.
The promoters named in the offer document include Dr. Ranjan Ramdas Pai, Manipal Global Health Services, MEMG International Ltd and three Singapore-incorporated investment holding companies, Kangto Investments, Imperius Healthcare Investments and Kabru Investments.
The Offer Structure
The IPO combines a fresh issue of up to Rs 8,000 crore with an offer for sale of up to 2,16,13,834 equity shares by selling shareholders, per the RHP. At the upper end of the Rs 560 to Rs 590 band, the offer-for-sale portion works out to roughly Rs 1,275 crore, taking the total offer to about Rs 9,275 crore. The face value is Rs 2 per share, the bid lot is 25 shares, and eligible employees receive a discount of Rs 56 per share, per the exchange record. A single-lot retail application of 25 shares amounts to Rs 14,750 at the top of the band; readers working through allotment arithmetic may find Oquilia's lumpsum calculator or CAGR calculator useful, and prior coverage sits on the /news desk.
The company will not receive any proceeds from the offer for sale. Selling shareholders named in the RHP include Manipal Education and Medical Group India Private Limited, TPG SG Magazine Pte. Ltd. and Novo Holdings Invest Asia A/S, alongside promoter entities. The stated objects of the fresh issue are the repayment or prepayment of certain borrowings of subsidiary Manipal Hospitals Private Limited (Rs 5,552.76 crore) and the acquisition of a minority stake in stepdown subsidiary Sahyadri Hospitals Private Limited (Rs 574 crore), with the balance for general corporate purposes. The book-running lead managers are Kotak Mahindra Capital, Axis Capital, Goldman Sachs (India) Securities, Jefferies India, J.P. Morgan India, UBS Securities India and DBS Bank India; KFin Technologies is the registrar.
Risk Factors
The RHP sets out its risk factors from page 34, and several concern the concentration of the business. The company discloses that it derived 46.40%, 51.55% and 59.98% of its revenue from operations from its hospitals in Karnataka in Fiscals 2026, 2025 and 2024 respectively, and that disruption or policy change in that state could materially affect its operations. Among the risk factors, the company also notes it primarily generates revenue from inpatient care, so any inability to maintain admissions and occupancy rates could adversely affect its results.
The RHP lists a further concentration in clinical specialties, disclosing that CONGO-R specialties accounted for 64.30% of gross inpatient revenue in Fiscal 2026. The offer document also discloses exposure to legal claims and regulatory action arising from healthcare services, including claims of alleged medical negligence, and a reliance on insurance and third-party administrators, which contributed 49.68% of gross inpatient revenue in Fiscal 2026. The company further discloses that the offer is being made under Regulation 6(2) of the SEBI ICDR Regulations because its net tangible assets were below the threshold under Regulation 6(1)(a) in Fiscal 2026.
What Happens Next
With bidding having closed on 31 July 2026, the registrar, KFin Technologies, will reconcile applications against the shares on offer and finalise the basis of allotment. Applications that are not allotted shares will have their blocked funds released through the ASBA and UPI mandate mechanism, while successful applicants will receive shares in their demat accounts ahead of listing. The UPI mandate confirmation cut-off was 5:00 PM on the closing day, per the exchange notice.
The shares are due to list on the NSE and BSE once the allotment process concludes and the exchanges issue their listing circulars, at which point the listing price will be set against the issue price. These are procedural steps in every book-built issue and are described here as process, not as any prediction of demand or price. The precise allotment and listing dates will be confirmed by the registrar and the exchanges.
FAQ
Should I apply for this IPO?
Oquilia does not make recommendations. This report is informational and is not investment advice or a recommendation to subscribe. The RHP, including the complete risk-factors section, is available on SEBI's website and the exchanges - read it directly before making any decision.
What is the price band and lot size?
The price band is Rs 560 to Rs 590 per equity share, per the RHP, with a face value of Rs 2. The bid lot is 25 shares, so a single-lot application at the upper end of the band amounts to Rs 14,750. Eligible employees receive a discount of Rs 56 per share.
How much was the issue subscribed?
As of 14:48 on the closing day, 31 July 2026, the issue was subscribed 3.88 times overall, per NSE data. The qualified institutional buyers' portion was subscribed 6.68 times and the employee portion 2.02 times, while the retail and non-institutional portions stood at 0.67 times and 0.50 times respectively.
What are the objects of the fresh issue?
Per the RHP, the fresh issue proceeds are earmarked for the repayment or prepayment of certain borrowings of subsidiary Manipal Hospitals Private Limited and for acquiring a minority stake in stepdown subsidiary Sahyadri Hospitals Private Limited, with the balance for general corporate purposes. The company receives no proceeds from the offer for sale.
Where can I read the RHP?
The red herring prospectus is filed with SEBI and available on its website under Filings, Public Issues, as well as on the NSE and BSE websites and the book-running lead managers' portals. It contains the complete financial statements and risk-factors section.
This report is based on the red herring prospectus filed with SEBI and subscription data from the NSE. It was surfaced via IPO coverage in The Economic Times.